Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.83 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | FAP | Q12884 | 1/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.37 |
| ▸ | LAP3 | P28838 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.34 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.34 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Valine SCHEMBL9399607 | 0.94 | SLC7A5 (0.83) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| Valine SCHEMBL19548431 | 0.92 | SLC7A5 (0.79) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| Valine SCHEMBL7704095 | 0.92 | SLC7A5 (0.79) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| Valine SCHEMBL7207898 | 0.92 | SLC7A5 (0.79) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| Valine SCHEMBL15602719 | 0.92 | SLC7A5 (0.88) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| Valine SCHEMBL27571970 | 0.92 | SLC7A5 (0.88) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| Valine SCHEMBL482773 | 0.92 | SLC7A5 (0.88) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| Valine SCHEMBL41225 | 0.91 | SLC7A5 (1.00) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| Valine SCHEMBL2785563 | 0.91 | SLC7A5 (1.00) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| Valine SCHEMBL8516 | 0.91 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550606-B2 | 9-cyano-substituted perylene-3,4-dicarboxylic acid monoimides | BASF AKTIENGESELLSCHAFT (DE) | 2009-06-23 | — | — | US | disclosed |
| US-20090023937-A1 | 9-CYANO-SUBSTITUTED PERYLENE-3,4-DICARBOXYLIC ACID MONOIMIDES | BASF AKTIENGESELLSCHAFT (DE) | 2009-01-22 | — | — | US | disclosed |
| US-7446198-B2 | 9-Cyano-substituted perylene-3, 4-dicarboxylic monoimides | BASF AKTIENGESELLSCHAFT (DE) | 2008-11-04 | — | — | US | disclosed |
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | METHLYGENE INC. (CA) | 2008-10-16 | — | — | US | disclosed |
| CN-100400514-C | 9-cyano-substituted perylene-3, 4-dicarboxylic monoimides | BASF AG (DE) | 2008-07-09 | — | — | CN | disclosed |
| WO-2008046216-A1 | KINASE INHIBITORS AND USES THEREOF | METHYLGENE, INC. (CA) | 2008-04-24 | — | — | WO | disclosed |
| WO-2008035209-A2 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2008-03-27 | — | — | WO | disclosed |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | METHYLGENE, INC. (CA) | 2008-01-03 | — | — | US | disclosed |
| US-20060229385-A1 | 9-Cyano-Substituted Perylene-3, 4-Dicarboxylic Monoimides | BASF AKTIENGESELLSCHAFT (DE) | 2006-10-12 | — | — | US | disclosed |
| CN-1681792-A | 9-cyano-substituted perylene-3,4-dicarboxylic acid monoimides | BASF AG (DE) | 2005-10-12 | — | — | CN | disclosed |
| US-5728867-A | LASER RECORDING | BASF AKTIENGESELLSCHAFT (DE) | 1998-03-17 | — | — | US | disclosed |
| US-4855283-A | IMMUNE SYSTEM STIMULANTS | BAYER AKTIENGESELLSCHAFT (DE) | 1989-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | ABL1, MAP3K20, MAP3K1 | SLC7A5 3833/4885SLC1A3 4254/4885SLC1A2 4382/4885 |
| US-20090023937-A1 | 9-CYANO-SUBSTITUTED PERYLENE-3,4-DICARBOXYLIC ACID MONOIMIDES | CA9, F9, CA13 | SLC7A5 1050/4885SLC1A3 102/4885SLC1A2 295/4885 |
| US-20060229385-A1 | 9-Cyano-Substituted Perylene-3, 4-Dicarboxylic Monoimides | CBR3, NR2C2, NR0B2 | SLC7A5 1367/4885SLC1A3 1090/4885SLC1A2 1617/4885 |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | HGF, ERBB2, MET | SLC7A5 3469/4885SLC1A3 4314/4885SLC1A2 4252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.